Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

F Hoffmann la Roche Ag
F Hoffmann la Roche Ag roche Glycart Ag

F Hoffmann la Roche Ag patents


Recent patent applications related to F Hoffmann la Roche Ag. F Hoffmann la Roche Ag is listed as an Agent/Assignee. Note: F Hoffmann la Roche Ag may have other listings under different names/spellings. We're not affiliated with F Hoffmann la Roche Ag, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "F" | F Hoffmann la Roche Ag-related inventors


Antisense oligonucleotides for modulating htra1 expression

The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.... F Hoffmann la Roche Ag

Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease

which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.... F Hoffmann la Roche Ag

Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.... F Hoffmann la Roche Ag

Oligonucleotides for reduction of pd-l1 expression

The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV... F Hoffmann la Roche Ag

Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease

which are useful in treating, ameloriating or preventing a viral disease, in particular influenza.... F Hoffmann la Roche Ag

Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds

The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d] pyrimidin-4-yl)piperazine and N-protected derivatives thereof, which may be used as an intermediate in the synthesis of Ipatasertib (i.e., (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)-propan-1-one). The present disclosure additionally relates to various compounds that are intermediates employed... F Hoffmann la Roche Ag

Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists

Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release... F Hoffmann la Roche Ag

Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein

Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).... F Hoffmann la Roche Ag

Compounds for treating spinal muscular atrophy

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.... F Hoffmann la Roche Ag

Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza

which is useful in treating, ameliorating or preventing influenza. Furthermore, specific combination therapies are disclosed.... F Hoffmann la Roche Ag

Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease

which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.... F Hoffmann la Roche Ag

Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease

which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.... F Hoffmann la Roche Ag

Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease

which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.... F Hoffmann la Roche Ag

Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy

A method is provided for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or for determining the continuation of GPC3-targeting drug therapy for a patient treated with GPC3-targeting therapy. The method includes determining the number of an immunocyte or... F Hoffmann la Roche Ag

Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof

The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as... F Hoffmann la Roche Ag

Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease

which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.... F Hoffmann la Roche Ag








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with F Hoffmann la Roche Ag in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for F Hoffmann la Roche Ag with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###